Transplantation of hESC-Derived Astrocytes (AstroRx) in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Enrolment: 16 · Results not recorded
Loading the evidence…
Biologic · ChEMBL not queried: AAV-transduced cell therapy, no chemical entity. MODALITY-LEVEL translation only. NO human trial uses glial-restricted precursors or GLT1/EAAT2 overexpression. The single recorded trial (AstroRx) uses human EMBRYONIC STEM CELL-derived astrocytes in ALS: a different cell source, no transgene, and a neurodegenerative rather than injury indication. The other 2 raw hits (NCT03453047, NCT04042272) were REJECTED as observational S100B/NSE biomarker studies with no cell intervention.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Amyotrophic Lateral Sclerosis
Enrolment: 16 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Unilateral C4 hemicontusion with the Infinite Horizon impactor, 1.5 mm tip at 395 kdyn, after right-sided C4 laminectomy
GLT1-overexpressing astrocyte transplants reduced lesion size and motor neuron loss, increased intact dorsal hemidiaphragm neuromuscular junctions and improved diaphragm EMG and compound muscle action potential amplitudes relative to medium controls, with grip strength unchanged.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.